BAT6021 + tislelizumab

BAT6021 + tislelizumab is a combination of two monoclonal antibody drugs under investigation for the treatment of advanced and metastatic solid tumors. BAT6021 is a monoclonal antibody inhibitor targeting TIGIT (T cell immunoglobulin and ITIM domains), designed to block immune suppression and enhance anti-tumor responses. Tislelizumab is an anti–PD-1 monoclonal antibody that blocks the Programmed Death-1 pathway to restore and promote T cell-mediated immune responses against tumor cells. This combination aims to simultaneously inhibit immune checkpoints that regulate T cell activity, potentially resulting in improved anti-cancer efficacy. The developer and lead sponsor of clinical studies of BAT6021 and its combinations is Bio-Thera Solutions. Clinical investigation has focused on safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy, with dose escalation and expansion cohorts for monotherapy and combination treatment[1][2][3].

Other names

BAT6021 + tislelizumab